Loading
Breast Cancer Treatment Studies / HER2/EGFR in Cancer Research / Advanced Breast Cancer Therapies · Journal article
Research in Health Science · September 7, 2026
Encouraging direction, but not yet definitive.
This is a single-center, unblinded randomized trial showing that trastuzumab plus pertuzumab combined with TCb chemotherapy improved objective response rate and pathological complete response compared to TCb alone in neoadjuvant HER2-positive breast cancer, with corresponding reductions in serum tumor markers and no increase in adverse events. The result is clinically plausible and internally consistent, but relies on surrogate endpoints rather than survival or recurrence outcomes, and lacks methodological detail on allocation concealment and blinding.
Randomized controlled trial, two-arm parallel, unblinded. HER2-positive breast cancer patients admitted to hospital between June 2023 and December 2025 undergoing neoadjuvant chemotherapy.. Intervention: TCb regimen (docetaxel + carboplatin) combined with trastuzumab and pertuzumab (dual-targeted therapy), 6 cycles. Compared with: TCb regimen (docetaxel + carboplatin) alone, 6 cycles. n = 112. Single center (specific country/region not stated)..
The observation group (dual-targeted therapy + TCb) had higher ORR compared to control group (TCb alone) The observation group had higher pCR rate compared to the control group Serum levels of CEA, CA125, and CA153 were significantly lower in the observation group after treatment (P <0.05)
No blinding reported; vulnerable to bias in response assessment and adverse event recording. No statistically significant difference in incidence of adverse reactions between groups (P > 0.05)
If confirmed in larger, blinded trials with hard clinical endpoints, dual-targeted therapy combined with TCb may become standard neoadjuvant regimen for HER2-positive breast cancer. At present, the surrogate endpoint improvements and lack of blinding warrant cautious interpretation pending confirmatory data on recurrence and survival.
A randomized controlled trial with a clear efficacy signal (higher ORR and pCR with dual-targeted therapy) and favorable tumor marker reduction, but with surrogate endpoints and no hard clinical outcomes reported.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in larger, blinded trials with hard clinical endpoints, dual-targeted therapy combined with TCb may become standard neoadjuvant regimen for HER2-positive breast cancer. At present, the surrogate endpoint improvements and lack of blinding warrant cautious interpretation pending confirmatory data on recurrence and survival.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective: To investigate the clinical efficacy of the trastuzumab plus pertuzumab (biclusal targeted therapy) combined with the TCb regimen (docetaxel + carboplatin) in neoadjuvant chemotherapy for HER2-positive breast cancer, as well as its impact on serum tumor markers. Methods: A total of 112 HER2-positive breast cancer patients admitted to our hospital between June 2023 and December 2025 were enrolled and randomly assigned into two groups using a random number table: the observation group (n = 56) and the control group (n = 56). The control group received the TCb chemotherapy regimen, while the observation group received the TCb regimen combined with trastuzumab and pertuzumab as dual-targeted therapy; both groups underwent a total of 6 cycles of treatment. The objective response rate (ORR) and pathological complete response (pCR) rate were compared between the two groups. Serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), and carbohydrate antigen 153 (CA153) were measured before and after treatment, and the incidence of adverse reactions was recorded. Results: The observation group exhibited a higher ORR and pCR rate compared to the control group. After treatment, the serum levels of CEA, CA125, and CA153 in the observation group were lower than those in the control group (P <0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The use of the dual-targeted therapy combined with the TCb regimen can enhance the efficacy of neoadjuvant chemotherapy in HER2-positive breast cancer, reduce serum tumor marker levels, and does not significantly increase the incidence of adverse reactions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.